In contrast to the postulations, it was recently shown that inhibition of NF-κB resulted in increased cytokine release and immunogenicity of PDT-treated tumor cells in vitro [274] and suggested that NF-κB may not be a suitable target for pharmacological inhibition in conjunction with PDT. The gene discussed is NFKB1; the disease is neoplasm.